Tekla Capital Management LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 155 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.

Quarter-by-quarter ownership
Tekla Capital Management LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q2 2023$8,322,464
-10.8%
131,435
-23.7%
0.33%
-8.2%
Q1 2023$9,333,890
+2.3%
172,3710.0%0.36%
+2.9%
Q4 2022$9,121,873
+13.7%
172,3710.0%0.34%
+5.2%
Q3 2022$8,020,000
-42.3%
172,371
-29.2%
0.33%
-39.9%
Q2 2022$13,895,000
-21.9%
243,437
-16.3%
0.55%
-12.6%
Q1 2022$17,802,000
+43.8%
290,936
+23.0%
0.62%
+57.0%
Q4 2021$12,376,000
+2.3%
236,447
-27.1%
0.40%
+2.3%
Q3 2021$12,094,000
+46.1%
324,401
+60.0%
0.39%
+44.6%
Q2 2021$8,276,000
+4.9%
202,756
-12.8%
0.27%
-0.7%
Q1 2021$7,888,000
-32.3%
232,476
-36.5%
0.27%
-33.7%
Q4 2020$11,644,000
+381.6%
366,176
+288.6%
0.41%
+349.5%
Q3 2020$2,418,000
-0.0%
94,2380.0%0.09%
-1.1%
Q2 2020$2,419,000
+67.1%
94,2380.0%0.09%
+41.5%
Q1 2020$1,448,000
-55.2%
94,2380.0%0.06%
-46.7%
Q4 2019$3,233,000
+1469.4%
94,238
+242.1%
0.12%
+1255.6%
Q3 2019$206,000
-71.2%
27,548
-50.0%
0.01%
-69.0%
Q2 2019$715,000
-46.7%
55,096
-50.0%
0.03%
-47.3%
Q1 2019$1,342,000
+6.9%
110,1930.0%0.06%
+1.9%
Q4 2018$1,255,000
+66.0%
110,193
+216.2%
0.05%
+100.0%
Q3 2018$756,000
-89.6%
34,850
-81.4%
0.03%
-90.9%
Q2 2016$7,290,000
+39.6%
187,8000.0%0.30%
+34.2%
Q1 2016$5,221,000
-48.3%
187,8000.0%0.22%
-39.3%
Q4 2015$10,102,000
+68.2%
187,800
+25.2%
0.37%
+69.4%
Q3 2015$6,006,000
-17.2%
150,000
-34.0%
0.22%
-17.9%
Q2 2015$7,258,000
+102.6%
227,164
+51.4%
0.26%
+85.2%
Q1 2015$3,582,000150,0000.14%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q2 2020
NameSharesValueWeighting ↓
DCF Advisers, LLC 359,000$18,790,0007.62%
Velan Capital Investment Management LP 150,000$7,851,0006.09%
SILVERARC CAPITAL MANAGEMENT, LLC 195,000$10,206,0004.14%
Vantage Consulting Group Inc 226,670$11,864,0003.19%
Vahanian & Associates Financial Planning Inc. 71,742$3,755,0003.03%
Nicholas Investment Partners, LP 652,886$34,172,0002.16%
COOPER/HAIMS ADVISORS, LLC 61,116$3,199,0001.97%
Bellevue Group AG 3,628,919$189,938,0001.96%
WASATCH ADVISORS LP 8,235,171$431,029,0001.76%
Quantum Private Wealth, LLC 77,622$4,062,0001.54%
View complete list of INTRA CELLULAR THERAPIES INC shareholders